The LiBBY trial found that an oral THC/CBD combination significantly reduced agitation in adults with advanced dementia, but the full safety picture behind that result is still incomplete. Overall side-effect rates were similar between the drug and placebo groups, while serious adverse events were more common with the drug — and investigators have said none were linked to the treatment itself, according to European Medical Journal's coverage of the AAIC 2026 presentation. For readers managing memory concerns or caring for someone with dementia, the trial is a notable scientific result, not a treatment option available today. The drug tested, known as T2, remains investigational, was studied only in a narrow, late-stage population, and has not been reviewed by any regulator.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Was the LiBBY Trial and What Did It Show?
- What Do the Safety Numbers Actually Say?
- Did Patients Die in the Trial, and Was That Linked to the Drug?
- Who Does This Apply To — and Who Does It Not?
- Is T2 Available, and What Should Caregivers Do Now?
- Frequently Asked Questions
What Was the LiBBY Trial and What Did It Show?
LiBBY stands for "Life's End Benefits of Cannabidiol and Tetrahydrocannabinol." It was a 12-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 study that enrolled 120 hospice-eligible adults with advanced Alzheimer's disease or other dementias, according to its registration on ClinicalTrials.gov. The trial tested whether a combination of THC and CBD could ease agitation, a common and distressing symptom in advanced dementia that includes restlessness, aggression, and resistance to care. Participants received the study drug, T2, starting at a half dose — 2 mg THC and 100 mg CBD twice daily — for the first week, then stepped up to a full dose of 4 mg THC and 200 mg CBD twice daily, or a matching placebo, through the remaining 11 weeks, according to a news release from Georgetown University School of Medicine.
Topline results were presented in July 2026 at the Alzheimer's Association International Conference in London. The trial met its primary endpoint: roughly 84% of participants on T2 improved on the Cohen-Mansfield Agitation Inventory, a standard measure of agitation symptoms, within two weeks, compared with about 31% on placebo. That gap held through the full 12 weeks, according to the Alzheimer's Association's AAIC 2026 release.
What Do the Safety Numbers Actually Say?
Adverse events of any kind occurred at similar rates in both groups — about 46.7% of participants on T2 and 42.4% on placebo, according to European Medical Journal's AAIC coverage. That similarity is reassuring for day-to-day tolerability: nausea, sedation, and similar common side effects did not spike dramatically with the active drug. The more serious figure is the gap in serious adverse events, which include hospitalizations, life-threatening complications, or death. These occurred in 23.3% of the T2 group versus 11.9% of the placebo group.
Investigators reviewed each serious adverse event and judged that none were related to the study drug, per the same European Medical Journal report. That judgment matters, but it is also where the public record is thinnest. A report tied to MediPharm Labs, the company supplying the formulation, noted that the initial topline announcement did not include a full breakdown of safety or tolerability data — meaning the percentages above come from conference and press coverage, not a peer-reviewed safety paper, according to Pharmacally's coverage. Readers should treat these numbers as early and subject to revision once a full publication appears.
Did Patients Die in the Trial, and Was That Linked to the Drug?
Being Patient reported that lead investigator Jacobo Mintzer, M.D., said the serious adverse events tallied in the trial included patient deaths, which he attributed to causes unrelated to treatment. Mintzer also said death rates did not differ between the treatment and placebo arms during the trial's open-label extension phase, according to Being Patient's report. This detail is important context given the higher rate of serious adverse events in the T2 group, but it has not been independently confirmed with a specific death count in any other source reviewed here.
Readers should understand this as the investigator's stated interpretation, not yet a verified, itemized accounting. A published safety analysis — rather than conference remarks — would be the place to confirm exact numbers and causes. It's also worth noting who was enrolled: all participants were hospice-eligible, meaning they already had advanced, life-limiting illness. Deaths in this population, during any trial, are expected at some rate regardless of treatment, which is part of why investigators compare death rates between the drug and placebo arms rather than treating any single death as alarming on its own.
Who Does This Apply To — and Who Does It Not?
The population studied was narrow by design: hospice-eligible adults with advanced Alzheimer's disease or other dementias who also had clinically significant agitation, according to the trial's ClinicalTrials.gov registration. That means the safety and efficacy results cannot be extended to adults with early memory concerns, mild cognitive impairment, or earlier-stage dementia without agitation as a prominent symptom. If you or someone you care for is in an earlier stage of memory loss, the LiBBY results don't tell you anything about how THC/CBD would affect you specifically.
The trial says something meaningful about a very specific clinical situation — severe agitation at the end of life — not about cannabinoids and dementia broadly. The study was funded primarily by the National Institute on Aging, part of the National Institutes of Health, and run through the NIA-funded Alzheimer's Clinical Trial Consortium. MediPharm Labs supplied its proprietary cannabinoid formulation for the research, according to a release carried by Barchart. That funding structure means the trial was designed and overseen as independent academic research, not run solely by the company that stands to benefit commercially.
Is T2 Available, and What Should Caregivers Do Now?
No regulatory body has approved T2, and no New Drug Application or other clearance has been reported. The compound remains investigational, and as of the most recent coverage, no Phase 3 trial — the larger study typically required before approval — had been announced, according to Being Patient's reporting.
That leaves a practical gap: there is no approved THC/CBD product that a clinician can prescribe for dementia-related agitation based on these results. Any cannabinoid use for this purpose outside the trial's open-label extension is off-label and has not been verified by the kind of safety review that would normally accompany an approved drug, per Georgetown's news release. For caregivers weighing options now:.
- Treat current cannabinoid products marketed for agitation or dementia symptoms as unverified for this specific use — the LiBBY formulation and dosing (2–4 mg THC with 100–200 mg CBD) was a controlled, clinically supervised regimen, not a retail product.
- Ask a treating physician about agitation management options that already have an established safety record, since T2 is not yet one of them.
- Watch for publication of the full LiBBY safety data, which would clarify the serious-adverse-event findings beyond the current conference-level summary.
- Confirm that any information about a Phase 3 trial or regulatory filing comes from a primary or verified source before acting on it, since none has been confirmed as of the most recent reporting.
Frequently Asked Questions
Is the LiBBY trial drug available for purchase or prescription?
No. T2 is investigational, with no regulatory approval and no Phase 3 trial announced as of the most recent reporting, per Being Patient.
Were the serious adverse events caused by the THC/CBD drug?
Investigators judged that none of the serious adverse events were related to the study drug, according to European Medical Journal's coverage of the AAIC 2026 presentation.
Does the LiBBY trial apply to people with early-stage memory loss?
No. It enrolled only hospice-eligible adults with advanced dementia and significant agitation, so the results don't generalize to earlier-stage memory concerns, per the trial's ClinicalTrials.gov listing.
You Might Also Like
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: What Is Established and What Remains Uncertain for Adults With Memory Concerns
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: What Is Established and What Remains Uncertain for Adults With Memory Concerns
- Blood Biomarker Counseling After the AAIC 2026 Findings: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
